<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Adenylate Cyclase 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate cyclase 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>2p23.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[109](https://www.ncbi.nlm.nih.gov/gene/109)</td></tr>
<tr><td><strong>OMIM</strong></td><td>600019</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000138031</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O60236](https://www.uniprot.org/uniprot/O60236)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Obesity, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Adenylate Cyclase 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate cyclase 3</td></tr>
<tr><td><strong>Chromosome</strong></td><td>2p23.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[109](https://www.ncbi.nlm.nih.gov/gene/109)</td></tr>
<tr><td><strong>OMIM</strong></td><td>600019</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000138031</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O60236](https://www.uniprot.org/uniprot/O60236)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Obesity, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>
ADCY3 (Adenylate Cyclase 3) is a member of the adenylate cyclase family of enzymes that catalyze the conversion of ATP to cyclic AMP (cAMP), a ubiquitous second messenger critical for cellular signaling. ADCY3 is a membrane-bound enzyme enriched in olfactory epithelium, hypothalamus, and various brain regions involved in energy homeostasis, reward processing, and circadian rhythm regulation. In the central nervous system, ADCY3 plays essential roles in dopaminergic signaling, synaptic plasticity, learning and memory, and neuroinflammation modulation.[@tang2016] Genetic variants in ADCY3 have been implicated in obesity, type 2 diabetes, and neuropsychiatric disorders, with emerging evidence suggesting a role in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD).[@wang2020] The enzyme's position at the intersection of G protein-coupled receptor (GPCR) signaling and cAMP-dependent pathways makes it a potential therapeutic target for modulating neuronal function in neurodegeneration.[@liu2019]
The ADCY3 gene is located on chromosome 2p23.3 and consists of 22 coding exons spanning approximately 28 kilobases. The gene encodes a protein of 1,244 amino acids with a molecular weight of approximately 140 kDa. ADCY3 belongs to the class III adenylate cyclase family, which is conserved from bacteria to mammals. The protein structure includes twelve transmembrane helices organized as six membrane-spanning segments repeated twice, forming a pseudosymmetric architecture. The catalytic domains are located in the cytoplasm, with the C1a and C2a domains forming the active site that binds ATP and magnesium ions required for cAMP synthesis.
ADCY3 catalyzes the conversion of ATP to cAMP through a mechanism involving two conserved catalytic domains. The enzyme requires magnesium ions as a cofactor for optimal activity. ADCY3 is uniquely regulated by multiple inputs: it is activated by the Gαs subunit of heterotrimeric G proteins and inhibited by Gαi/o subunits. Additionally, ADCY3 is activated by calcium ions through calmodulin (CaM) binding, distinguishing it from many other adenylate cyclase isoforms. This dual regulation by G proteins and calcium allows ADCY3 to integrate multiple signaling pathways and respond to diverse extracellular stimuli.
ADCY3 activity is regulated at multiple levels. At the transcriptional level, ADCY3 expression is controlled by various transcription factors including CREB (cAMP Response Element-Binding protein), which is itself activated by cAMP-dependent protein kinase A (PKA). Post-translational modifications including phosphorylation and palmitoylation modulate ADCY3 localization and activity. The enzyme is also subject to feedback inhibition by cAMP itself through PKA-mediated phosphorylation. Cellular localization studies show ADCY3 is enriched in lipid rafts and synaptic membranes, positioning it optimally for GPCR signaling at synapses and neuronal process.
ADCY3 contains twelve transmembrane helices divided into two hydrophobic modules (M1 and M2), each containing six helices. These transmembrane domains are connected by extracellular and intracellular loops, with the catalytic domains located in the cytoplasm. The transmembrane domains serve both to anchor the enzyme in the plasma membrane and to position the catalytic domains for interaction with G protein subunits. The N-terminus of ADCY3 contains a leucine-zipper motif that may be involved in protein-protein interactions and dimerization.
The catalytic core of ADCY3 consists of two homologous domains: C1a (residues 366-481) and C2a (residues 808-934). These domains form a pseudosymmetric dimer that creates the catalytic site at their interface. The C1a domain binds the forskolin analog and Gαs subunits, while the C2a domain contributes to substrate binding and orientation. ATP binding occurs at the interface between these domains, with key residues including Asp404 and Asp829 coordinating the phosphate groups of ATP. The catalytic mechanism involves a metal ion-dependent attack on the α-phosphate of ATP, leading to the formation of cAMP and pyrophosphate.
ADCY3 is widely expressed throughout the brain with particularly high levels in olfactory epithelium, hypothalamus, hippocampus, cortex, basal ganglia, and cerebellum. In the olfactory epithelium, ADCY3 is expressed in olfactory sensory neurons where it plays a critical role in odor detection and signal transduction. In the hypothalamus, ADCY3 is enriched in the arcuate nucleus and paraventricular nucleus, regions critical for energy homeostasis and feeding behavior. In the hippocampus, ADCY3 is expressed in pyramidal neurons and interneurons, where it contributes to synaptic plasticity and memory formation. The basal ganglia express high levels of ADCY3, particularly in the striatum and substantia nigra, where dopaminergic signaling is prominent.
At the cellular level, ADCY3 localizes to the plasma membrane, particularly in dendritic spines and axon terminals. Subcellular fractionation studies demonstrate ADCY3 enrichment in synaptic membranes and lipid rafts. Immunohistochemistry in human brain tissue shows ADCY3 expression in neurons and astrocytes, with lower expression in microglia. The enzyme is also expressed in endothelial cells of the blood-brain barrier, where it may regulate vascular function and neurovascular coupling.
Multiple lines of evidence implicate ADCY3 dysregulation in Alzheimer's disease pathogenesis. The cAMP/PKA signaling pathway plays critical roles in synaptic plasticity, memory consolidation, and tau phosphorylation. In AD brains, cAMP signaling is globally dysregulated, with altered adenylate cyclase activity contributing to memory deficits. ADCY3, as a major neuronal adenylate cyclase isoform, is positioned to contribute to these changes. Post-mortem studies of AD brain tissue show reduced ADCY3 expression in the hippocampus and cortex, regions most affected by amyloid and tau pathology.
Amyloid-beta (Aβ) oligomers, the toxic species in AD, directly impair cAMP signaling through effects on adenylate cyclases. In vitro studies demonstrate that Aβ42 treatment reduces ADCY3 activity and cAMP production in hippocampal neurons. This reduction in cAMP signaling contributes to synaptic dysfunction and impairs long-term potentiation (LTP), a cellular correlate of learning and memory. The relationship between Aβ and cAMP signaling creates a vicious cycle where Aβ impairs cAMP signaling, which then reduces the activity of cAMP-dependent protective pathways.
Emerging evidence links ADCY3 to tau pathology in AD. Studies in mouse models show that genetic deletion of ADCY3 exacerbates tau phosphorylation and aggregation. Conversely, pharmacologic activation of cAMP signaling reduces tau pathology through PKA-mediated phosphorylation of tau at protective sites. The mechanism involves PKA-dependent activation of protein phosphatase 2A (PP2A), which dephosphorylates pathogenic tau epitopes. These findings suggest that ADCY3 dysfunction may contribute to tau pathology progression.
ADCY3 also modulates neuroinflammation in AD through cAMP-dependent regulation of microglia and astrocytes. In microglia, cAMP signaling generally exerts anti-inflammatory effects, reducing pro-inflammatory cytokine production and promoting a protective phenotype. ADCY3 deficiency in microglia leads to enhanced inflammatory responses to Aβ, while ADCY3 activation reduces neuroinflammation. This suggests therapeutic potential for adenylate cyclase modulators in AD treatment.
In Parkinson's disease, ADCY3 plays critical roles in dopaminergic signaling in the striatum. Dopamine D1 receptors (D1R) couple to Gαs and activate adenylate cyclases, including ADCY3, to increase cAMP production. This signaling pathway is essential for motor control and reward processing. In PD, the loss of dopaminergic neurons leads to dysregulation of D1R signaling and altered cAMP dynamics in the striatum. Studies in animal models of PD demonstrate that ADCY3 expression and activity are modulated by dopaminergic degeneration.
ADCY3-mediated cAMP signaling regulates mitochondrial function through PKA-dependent phosphorylation of mitochondrial proteins. In PD, mitochondrial dysfunction is a central pathogenic mechanism, with mutations in PINK1, PARKIN, and LRRK2 causing familial PD. cAMP signaling influences mitochondrial biogenesis, dynamics, and quality control through regulation of PGC-1α (PPARGGC1A) and other transcriptional co-activators. ADCY3 dysfunction may therefore contribute to mitochondrial deficits in PD.
Similar to AD, ADCY3 modulates neuroinflammation in PD. Microglial activation and neuroinflammation contribute to dopaminergic neuron degeneration. cAMP-elevating agents reduce microglial activation and protect dopaminergic neurons in experimental models. ADCY3 activation represents a potential approach to dampening neuroinflammation in PD, though the therapeutic window must be carefully considered given the complex role of cAMP in different cell types.
The position of ADCY3 at the intersection of GPCR signaling and cAMP production makes it an attractive therapeutic target. Several strategies have been explored:
Recent drug development efforts have focused on identifying ADCY3-selective modulators. Virtual screening approaches have identified compounds that selectively enhance ADCY3 activity. These molecules show promise in cellular models of neurodegeneration, though in vivo efficacy and blood-brain barrier penetration remain challenges. Additionally, allele-specific approaches targeting disease-associated ADCY3 variants are being explored.
Gene therapy targeting ADCY3 represents a longer-term therapeutic strategy. AAV-mediated ADCY3 expression has been tested in preclinical models, with some success in restoring cAMP signaling and protecting neurons. However, precise targeting and expression level control remain challenges. The complexity of cAMP signaling, with its diverse and sometimes opposing effects in different cell types, complicates therapeutic targeting.
ADCY3 plays crucial roles in synaptic transmission:
Presynaptic Function:
ADCY3 is essential for LTP:
Induction Phase:
ADCY3 receives signals from multiple GPCRs:
Gαs-coupled receptors:
ADCY3 produces cAMP that activates multiple downstream pathways:
PKA Signaling:
ADCY3 in energy homeostasis:
Arcuate Nucleus:
ADCY3 affects peripheral tissues:
Adipose Tissue:
ADCY3 participates in circadian regulation:
SCN Function:
ADCY3 in sleep-wake cycles:
Wake Promotion:
ADCY3 contributes to memory processes:
Hippocampal Function:
ADCY3 dysfunction in cognitive disorders:
Alzheimer's Disease:
ADCY3 modulates microglial function:
Anti-inflammatory Effects:
ADCY3 in astrocyte biology:
glutamate Uptake:
ADCY3 is highly expressed in olfactory sensory neurons:
Signal Transduction:
ADCY3 olfactory function relates to disease:
Direct Activators:
Viral Delivery:
Global Knockout:
Overexpression:
Enzyme Assays:
Live Cell Imaging:
Diagnostic Markers:
Therapeutic Approaches:
The following diagram shows the key molecular relationships involving ADCY3 — Adenylate Cyclase 3 discovered through SciDEX knowledge graph analysis: